Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE). (3rd June 2019)

• Record Type: Journal Article
• Authors: Eberl, Anja; Hallinen, Taru; af Björkesten, Clas-Göran; Heikkinen, Markku; Hirsi, Eija; Kellokumpu, Mikko; Koskinen, Inka; Moilanen, Veikko; Nielsen, Christian; Nuutinen, Heikki; Suhonen, Ulla-Maija; Utriainen, Karri; Vihriälä, Ilkka; Soini, Erkki; Wennerström, Christina; Nissinen, Riikka; Borsi, Andras; Koivunen, Minni; Tillonen, Jyrki; Sipponen, Taina
• Is Part Of: Scandinavian journal of gastroenterology. Volume 54:Number 6(2019)
• Page Start: 718
• Page End: 725
• Publication Date: 2019-06-03
• Subjects: Crohn's disease -- biomarkers -- biologics -- inflammatory bowel disease -- IL-12/23 -- ustekinumab -- endoscopic remission; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2019.1624817
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn's Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patients receiving UST to provide guidance in UST treatment in the era of increasing prevalence of CD. Methods: The study assessed UST treatment patterns such as dosing frequency, concomitant medication and persistence in 48 CD patients commencing UST therapy in 12 Finnish hospitals during 2017. Clinical remission and response rates were explored using a modified Harvey–Bradshaw index (mHBI) and endoscopic response via the simple endoscopic score for Crohn's disease (SES-CD) as proportions of patients at week 16 and at the end of follow-up. Results: Forty patients (83%) continued UST-treatment at the end of follow-up. At week 16, clinical response and endoscopic healing was observed, where data were available; mHBI decreased from 9 to 3 ( p = .0001) and SES-CD from 12 to 3 ( p = .009). Clinical benefit was achieved by 83% (19/23) at week 16 and by 76% (16/21) at the end of follow-up. The proportion of patients using corticosteroids decreased from 48% to 25% at week 16 and to 13% at the end of the follow-up. Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endoscopic response in this real-life nationwide study of CD patients. Significant corticosteroid tapering in patients with highly treatment refractory and long-standing CD was observed.